Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 3/2010

01-03-2010 | Commentary

Oxidative stress and glucose metabolism—is there a need to revisit effects of insulin treatment?

Author: P. M. Humpert

Published in: Diabetologia | Issue 3/2010

Login to get access

Excerpt

Oxidative stress induced by hyperglycaemia and subsequent cellular damage is thought to be one of the major pathophysiological factors causing late complications in diabetes [1, 2]. Hyperglycaemia-dependent superoxide overproduction by the mitochondrial electron transport chain plays a key role in the cellular activation leading to endothelial damage. The generation of reactive oxygen species also involves an increased polyol and hexosamine pathway flux as well as activation of protein kinase C and excess formation of advanced glycation end-products [1]. These pathways lead to pro-inflammatory cell activation and subsequent endothelial dysfunction in diabetes [1, 3]. …
Literature
1.
Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625CrossRefPubMed
2.
Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599–622CrossRefPubMed
3.
Bierhaus A, Humpert PM, Morcos M et al (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876–886CrossRefPubMed
4.
Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P (2000) Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 85:2970–2973CrossRefPubMed
5.
Schiekofer S, Andrassy M, Chen J et al (2003) Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 52:621–633CrossRefPubMed
6.
Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Jama 295:1681–1687CrossRefPubMed
7.
Monnier L, Colette C, Mas E et al (2009) Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. doi:10.​1007/​s00125-009-1574-6 PubMed
8.
Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903CrossRefPubMed
9.
Raz I, Wilson PW, Strojek K et al (2009) Effects of prandial vs fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381–386CrossRefPubMed
10.
Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JB, Devries JH (2009) Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 52:2229–2232CrossRefPubMed
11.
Del Prato S (2009) Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 52:1219–1226CrossRefPubMed
12.
Bravi MC, Armiento A, Laurenti O et al (2006) Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism 55:691–695CrossRefPubMed
13.
Bierhaus A, Nawroth PP (2009) Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52:2251–2263CrossRefPubMed
14.
Aljada A, Ghanim H, Saadeh R, Dandona P (2001) Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 86:450–453CrossRefPubMed
15.
Dandona P, Aljada A, Mohanty P et al (2001) Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257–3265CrossRefPubMed
16.
Dandona P, Chaudhuri A, Ghanim H, Mohanty P (2009) Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol 53:S14–S20CrossRefPubMed
17.
Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD (1994) Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94:1172–1179CrossRefPubMed
18.
Tamminen M, Westerbacka J, Vehkavaara S, Yki-Jarvinen H (2002) Insulin-induced decreases in aortic wave reflection and central systolic pressure are impaired in type 2 diabetes. Diabetes Care 25:2314–2319CrossRefPubMed
19.
Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S, Yki-Jarvinen H (1999) Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. Hypertension 33:1118–1122PubMed
20.
Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H (2000) Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 20:545–550PubMed
21.
Humpert PM, Djuric Z, Zeuge U et al (2008) Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor-dependent signaling. Mol Med 14:301–308CrossRefPubMed
22.
Humpert PM, Neuwirth R, Battista MJ et al (2005) SDF-1 genotype influences insulin-dependent mobilization of adult progenitor cells in type 2 diabetes. Diabetes Care 28:934–936CrossRefPubMed
23.
Fadini GP, Baesso I, Agostini C et al (2008) Maternal insulin therapy increases fetal endothelial progenitor cells during diabetic pregnancy. Diabetes Care 31:808–810CrossRefPubMed
24.
Ceolotto G, Bevilacqua M, Papparella I et al (2004) Insulin generates free radicals by an NAD(P)H, phosphatidylinositol 3′-kinase-dependent mechanism in human skin fibroblasts ex vivo. Diabetes 53:1344–1351CrossRefPubMed
25.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077CrossRefPubMed
26.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Jama 290:486–494CrossRefPubMed
27.
Conway B, Costacou T, Orchard T (2009) Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes? Diab Vasc Dis Res 6:223–230CrossRef
28.
Patrignani P, Tacconelli S (2005) Isoprostanes and other markers of peroxidation in atherosclerosis. Biomarkers 10(Suppl 1):S24–S29CrossRefPubMed
29.
Lakka HM, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT (2000) Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 160:1160–1168CrossRefPubMed
Metadata
Title
Oxidative stress and glucose metabolism—is there a need to revisit effects of insulin treatment?
Author
P. M. Humpert
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1652-9

Other articles of this Issue 3/2010

Diabetologia 3/2010 Go to the issue

Article

Case fatality rates after first acute coronary syndrome in persons treated for type 2 diabetes show an improving trend

Article

Effects of glucose level on early and long-term mortality after intracerebral haemorrhage: the Acute Brain Bleeding Analysis Study

Article

Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes

Article

The gait and balance of patients with diabetes can be improved: a randomised controlled trial

Article

Nocturnal intermittent hypoxia and the development of type 2 diabetes: the Circulatory Risk in Communities Study (CIRCS)

Article

Human ATP synthase beta is phosphorylated at multiple sites and shows abnormal phosphorylation at specific sites in insulin-resistant muscle
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits